Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | LPL | P06858 | 1/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TTR | P02766 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16379257 | 0.85 | CA2 (0.41) | PDE2ALMNACA2LPLLIPG | |
| SCHEMBL22023199 | 0.79 | GRM1 (0.42) | KDM4EALDH1A1 | |
| SCHEMBL13065320 | 0.79 | CA1 (0.38) | CA2ENPP2CA1TTR | |
| SCHEMBL13158680 | 0.76 | PDE2A (0.32) | PDE2ACA2LPLLIPGCA1 | |
| SCHEMBL24852481 | 0.75 | CA2 (0.37) | PDE2ACA2LPLLIPGENPP2 | |
| SCHEMBL2427206 | 0.75 | PDE2A (0.56) | PDE2ALMNATP53HTTNEK1 | |
| SCHEMBL2427205 | 0.75 | PDE2A (0.56) | PDE2ALMNATP53HTTNEK1 | |
| SCHEMBL29668983 | 0.74 | PDE2A (0.60) | PDE2ALMNATP53HTTALDH1A1 | |
| SCHEMBL1761854 | 0.74 | PDE2A (0.60) | PDE2ALMNATP53HTTALDH1A1 | |
| SCHEMBL706808 | 0.74 | PDE2A (0.60) | PDE2ALMNATP53HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2680822-B1 | VESICLE COMPOSITIONS | SENSULIN LLC (US) | 2022-02-23 | — | — | EP | disclosed |
| US-9278068-B2 | Vesicle compositions | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-03-08 | — | — | US | disclosed |
| US-20140227349-A1 | Vesicle Compositions | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-08-14 | — | — | US | disclosed |
| US-8679531-B2 | Vesicle compositions | CENSE BIOSCIENCES, INC. | 2014-03-25 | — | — | US | disclosed |
| US-20120231067-A1 | VESICLE COMPOSITIONS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-09-13 | — | — | US | disclosed |
| WO-2012119117-A1 | VESICLE COMPOSITIONS | SENSULIN, LLC (US) | 2012-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120231067-A1 | VESICLE COMPOSITIONS | EXOSC5, EXOSC10, EXOSC9 | PDE2A 1863/4885LMNA 3426/4885TP53 20/4885 |
| US-20140227349-A1 | Vesicle Compositions | EXOSC5, EXOSC10, EXOSC9 | PDE2A 1863/4885LMNA 3426/4885TP53 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.